---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-023076"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:08:39.990929+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IDEAYA appoints Joshua Bleharski as CFO, effective May 2025

## Summary
- Joshua Bleharski, Ph.D., age 50, appointed Chief Financial Officer, effective early May 2025.
- Bleharski joins from J.P. Morgan, where he spent 17 years, most recently as Managing Director and Global Co-Head of Biopharma.
- Holds B.S. in Biology from Duke, Ph.D. in Immunology from UCLA, and MBA from UC Berkeley Haas.
- Compensation terms for Bleharski will be disclosed later via an amendment to this Form 8-K.

## SEC filing metadata
- accession: 0001193125-25-023076
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312525023076/0001193125-25-023076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312525023076/d934896d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-023076
- JSON: https://secwatch.observer/filing/0001193125-25-023076.json
- Plain text: https://secwatch.observer/filing/0001193125-25-023076.txt

## Key facts
- Executive change
  Joshua Bleharski was appointed as Chief Financial Officer at IDEAYA Biosciences, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On February 10, 2025, the Board of Directors (the “Board”) of IDEAYA Biosciences, Inc. (the “Company”) appointed Joshua Bleharski, Ph.D. as Chief Financial Officer of the Company, effective early May 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000119312525023076/0001193125-25-023076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.